Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL27168864 | 1.00 | KDM4E (0.39) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| Sulfuric Acid SCHEMBL1940139 | 1.00 | KDM4E (0.39) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| Sulfuric Acid SCHEMBL28888125 | 0.97 | KDM4E (0.38) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| SCHEMBL27168863 | 0.84 | CA2 (0.30) | — | |
| Methyl Carbamate SCHEMBL31246331 | 0.83 | KDM4E (0.39) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| Iodide SCHEMBL6991384 | 0.79 | — | — | |
| Water SCHEMBL27621372 | 0.79 | — | — | |
| SCHEMBL28202086 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL16369776 | 0.79 | — | — | |
| Bromide SCHEMBL28186818 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024221005-A2 | METHODS FOR INHIBITING RESISTANCE TO IMMUNE BLOCKADE INHIBITOR THERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-03-17 | — | — | US | claimed |
| US-20200038509-A1 | RADIOFREQUENCY FIELD HYPERTHERMIA AND SOLID TUMOR IMMUNOMODULATION | BAYLOR COLLEGE OF MEDICINE | 2020-02-06 | — | — | US | claimed |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-01-30 | — | — | US | claimed |
| CN-109880052-A | A kind of medical bandage coating preparation method of polyurethane resin compound material | 亳州科蔚科技服务有限公司 | 2019-06-14 | — | — | CN | claimed |
| WO-2018071837-A1 | RADIOFREQUENCY FIELD HYPERTHERMIA AND SOLID TUMOR IMMUNOMODULATION | BAYLOR COLLEGE OF MEDICINE (US) | 2018-04-19 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | claimed |
| WO-2007070983-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-06-28 | — | — | WO | claimed |
| EP-3746436-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2025-08-14 | — | — | US | disclosed |
| WO-2025097170-A1 | A METHOD OF MINIMIZING OR ELIMINATING NEPHROTOXICITY IN PATIENTS UNDERGOING TREATMENT WITH ANTIMICROBIAL OR ANTICANCER DRUGS | PROLETARIAT THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025093926-A1 | A METHOD OF MINIMIZING OR ELIMINATING NEPHROTOXICITY IN PATIENTS UNDERGOING CISPLATIN-BASED CHEMOTHERAPY VIA SEQUENTIAL ADMINISTRATION OF A PROTECTIVE AGENT FOLLOWED BY A TOXIC AGENT | AKIHIKO SAITO (JP) | 2025-05-08 | — | — | WO | disclosed |
| EP-0186045-A1 | 1,4-Dipyrimidinylbenzene derivative and liquid crystal composition containing it | Chisso Corporation (JP) | 1986-07-02 | — | — | EP | disclosed |
| US-4593030-A | Use of 6-aryluracils as antiinflammatory and antiarthritic agents | THE UPJOHN COMPANY (US) | 1986-06-03 | — | — | US | disclosed |
| US-4578466-A | Processes for the preparation of 6-aryluracils | THE UPJOHN COMPANY (US) | 1986-03-25 | — | — | US | disclosed |
| US-4521599-A | Process for the preparation of 1,3-oxazine-4-ones | THE UPJOHN COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| US-4495349-A | 6-Aryluracils | THE UPJOHN COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | KDM4E 1931/4885CYP2D6 152/4885CYP2C19 407/4885 |
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, PYGB | KDM4E 4434/4885CYP2D6 1304/4885CYP2C19 2098/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | KDM4E 4162/4885CYP2D6 970/4885CYP2C19 574/4885 |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | KDM4E 1931/4885CYP2D6 152/4885CYP2C19 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.